Personalized catheter plan aims to cut Re-Insertions after rectal cancer surgery
NCT ID NCT07346586
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a personalized plan for removing urinary catheters after mid-low rectal cancer surgery can reduce the need for re-insertion. About 1,545 patients will be randomly assigned to one of three groups: catheter removal at 24 hours, at 48 hours, or an individualized plan where high-risk patients get a medication (tamsulosin) before removal. The main goal is to see which strategy leads to the fewest patients needing a new catheter within a week.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tamsulosin
What this could lead to
If successful, this could lead to a standard, personalized plan for removing urinary catheters earlier after rectal cancer surgery, reducing discomfort and infection risk.
What could go wrong
This is a single-center trial that hasn't started yet. The results may not apply to all hospitals, and the personalized approach may not lower re-catheterization rates as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Hospital of Jilin University
Changchun, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••